Factors limiting the transmission of HIV mutations conferring drug resistance: Fitness costs and genetic bottlenecks

Scientific Reports

Volumn 2, Issue , 2012, Pages

  Wagner, Bradley G ^a   Garcia Lerma, J Gerardo ^b   Blower, Sally ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRAL RESISTANCE; ARTICLE; DISEASE TRANSMISSION; DRUG EFFECT; GENETICS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION;

DRUG RESISTANCE, VIRAL; HIV; HIV INFECTIONS; HUMANS;

EID: 84859744081     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep00320     Document Type: Article

References (38)

1. Heneine, W. When do minority drug-resistant HIV-1 variants have a major clinical impact? J Infect Dis 201, 647-649 (2010).
2. Paredes, R. et al. Pre-existing Minority drug-resistant HIV-1 variants, adherence, and risk of antiretrovrial treatment failure. J Infect Dis 201, 662-671 (2010).
3. Li, J. Z. et al. Low-frequency HIV-1 drug resistance mutations and risk of NNRTIbased antiretroviral treatment failure: a systematic review and pooled analysis. JAMA 305, 1327-1335 (2011).
4. Cong, M. E., Heneine, W. & Garcia-Lerma, J. G. The fitness cost of mutations associated with human immunodeficiency virus type 1 drug resistance is modulated by mutational interactions. J Virol. 81, 3037-3041 (2007). (Pubitemid 46447070)
5. Cong, M. E. et al. Generation and mucosal transmissibility of emtricitabine and tenofovir-resistant SHIV162P3 mutants in macaques. Virology 412, 435-440 (2011).
6. Haaland, R. E. et al. Inflammatory genital infections mitigate a severe genetic bottleneck in heterosexual transmission of subtype A and C HIV-1. PLoS Pathogens 5, e1000274 (2009).
7. Keele, B. F. et al. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc. Natl. Acad. Sci 105, 75552-75557 (2008).
8. Bennett, D. E. et al. Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PLoS ONE 4, e4724 (2009).
9. Miller, M. D. K65R, TAMs, and tenofovir. AIDS Reviews 6, 22-33 (2004).
10. Wainberg, M. et al. Development of HIV-1 resistance to (-) 2'-deoxy-3'-thiactytidine in patients with AIDS or advanced AIDS-related complex. AIDS 9, 351-357 (1995).
11. Garcia-Lerma, J. G., Nidtha, S., Blumoff, K., Weinstock, H. & Heneine, W. Increased ability for selection of zidovudine resistance in a distinct class of wild-type HIV-1 from drug-naive persons. Proc Natl Acad Sci USA 98, 13907-13912 (2001). (Pubitemid 33115997)
12. Pingen, M., Nijhuis, M., de Bruijn, J. A., Boucher, C. A. B. & Wensing, A. M. J. Evolutionary pathways of transmitted drug-resistant HIV-1. J Antimicrob Chemother 66, 1467-1480 (2011).
13. Perelson, A. S. & Ribeiro, R. M. Estimating drug efficacy and viral dynamic parameters: HIV and HCV. Stat Med 27, 4647-4657 (2008).
14. Attia, S., Egger, M., Müller, M., Zwahlen, M. & Low, N. Sexual transmission of HIV according to viral load and antiretroviral therapy: systematic review and meta-analysis. AIDS 23, 1397-1404 (2009).
15. San Francisco Department of Public Health HIV/AIDS epidemiology annual report (2008).
16. Paredes, R. et al. In vivo fitness cost of theM184V mutation in multidrug-resistant human immunodeficiency virus type 1 in the absence of lamivudine. J Virol 83, 2038-2043 (2009).
17. Goudsmit, J., de Ronde, A., de Rooij, E. & de Boer, R. Broad spectrum of in vivo fitness of human immunodeficiency virus type 1 subpopulations differing at reverse transcriptase codons 41 and 215. J Virol 71, 4479-4484 (1997). (Pubitemid 27204138)
18. Wei, X. et al. Minority HIVmutation detection in dried blood spots indicates high specimen integrity and reveals hidden archived drug resistance. J Clin Virol 50, 148-152 (2011).
19. Yerly, S. et al. Transmission of HIV-1 drug resistance in Switzerland: a 10-year molecular epidemiology survey. AIDS 21, 2223-2229 (2007). (Pubitemid 350287221)
20. Booth, C. L. & amp; Geretti, A. M. Prevalence and determinants of trasmitted antiretroviral drug resistance in HIV-1 infection. J Antimicrob Chemother 59, 1047-1056 (2007). (Pubitemid 47073314)
21. Gianella, S. & Richman, D. D. Minority variants of drug-resistant HIV. J Infect Dis 202, 657-666 (2010).
22. Johnson, J. A. et al. Simple PCR assays improve the sensitivity of HIV-1 subtype B drug resistance testing and allow linking of resistance mutations. PLoS ONE 2, e638 (2007).
23. Jakobsen, M. R. et al. Transmission of HIV-1 drug-resistant variants: prevalence and effect on treatment outcome. Clin Infect Dis 50, 566-573 (2010).
24. Kouyos, R. D. et al. Molecular epidemiology reveals long-term changes in HIV type 1 subtype B transmission in Switzerland. J Infect Dis 201, 1488-1497 (2010).
25. Jain, V. et al. Differential persistence of transmitted HIV-1 drug resistance mutation classes. J Infect Dis 203, 1174-1181 (2011).
26. Hué S., Gifford, R. J., Dunn, D., Fernhill, E. & Pillay, D. Demonstration of sustained drug resistant human immunodeficiency virus type 1 lineages circulating among treatment naive individuals. J Virol. 83, 2645-2654 (2009).
27. Shafer, R. W. Rationale and uses of a public HIV drug-resistance database. J Infect Dis 194, S51-80 (2006).
28. Rhee Soo-Yon et al. Human immunodeficiency virus reverse transcriptase and protease sequence database. Nucleic Acids Research 31, 298-303 (2003).
29. Liu, T. F. & Shafer, R. W. Web resources for HIV type 1 genotypic-resistance test interpretation. Clin Infect Dis 42, 1608-1618 (2006).
30. Callegaro, A. et al. Epidemiological network analysis in HIV-1 B infected patients diagnosed in Italy between 2000 and 2008. Infect Genet Evol 11, 624-632 (2011).
31. Ragonnet-Cronin, M. et al. Longitudinal phylogenetic surveillance identifies distinct patterns of cluster dynamics. J Acquir Immune Defic Syndr 55, 102-108 (2010).
32. Mare & acute;e, A. F., Keulen, L. M., Boucher, C. A. & amp; De Boer, R. J. Estimating relative fitness in viral competition experiments. J Virol. 74, 11067-11072 (2000). (Pubitemid 32223971)
33. De Boer, R. J., Ribeiro, R. M. & Perelson, A. S. Current estimates for HIV-1 production imply rapid viral clearance in lymphoid tissues. PLoS Comput Biol 6, e1000906 (2010).
34. Lyles, R. H. et al. Natural history of human immunodeficiency virus type 1 viremia after seroconversion and proximal to AIDS in a large cohort of homosexual men. Multicenter AIDS Cohort Study. J Infect Dis 181, 872-880 (2000). (Pubitemid 30194468)
35. Smith, R. J., Okano, J. T., Kahn, J. S., Bodine, E. N. & Blower, S. Evolutionary dynamics of complex networks of HIV drug-resistant strains: The case of San Francisco. Science 327, 697-701 (2010).
36. Blower, S. M. & Dowlatabadi, H. Sensitivity and uncertainty analysis of complex models of disease transmission: an HIVmodel, as an example. Int Stat Rev 2, 229-243 (1994).
37. Rodriguez, B. et al. Predictive value of plasmaHIVRNAlevel on rate of CD4 T-cell decline in untreated HIV infection. JAMA 296, 1498-1506 (2006). (Pubitemid 44465514)
38. Pillay, D. et al. The impact of transmitted drug resistance on the natural history of HIV infection and response to first-line therapy. AIDS 20, 21-28 (2006). (Pubitemid 41818110)